Iovance Biotherapeutics (IOVA) is back in focus after Australia’s Therapeutic Goods Administration granted conditional approval for Amtagvi, its tumor-infiltrating lymphocyte therapy for adults with previously treated advanced melanoma.

The TGA decision comes after a volatile period for the stock, with a 30 day share price return of 16.85% and year to date share price return of 67.86%. However, the 3 year total shareholder return has fallen 46.39% and the 5 year total shareholder return has fallen 81.96%, so recent momentum is building from a much weaker long term base.

If this kind of cancer therapy story has your attention, it can be useful to scan other early stage opportunities in healthcare focused AI by checking out 39 healthcare AI stocks

With Iovance trading at US$4.23, sitting on a 1 year total return of 106.34% yet still carrying an 82% decline over 5 years, the key question now is whether there is a genuine opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 49.3% Undervalued

Against the last close at $4.23, the most followed narrative pegs Iovance’s fair value at $8.35, framing the Australia news inside a much bigger earnings story.

Advancing multiple late-stage clinical programs for TIL therapies across solid tumor types (lung, endometrial, next-gen approaches) not only opens new addressable markets but also reduces reliance on Amtagvi alone, diversifying future revenue streams and stabilizing earnings outlook.

Want to see what sits underneath that potential shift, from single product reliance to a broader TIL portfolio? The narrative leans heavily on rapid revenue expansion, a swing from losses to profits, and a future earnings multiple that assumes strong confidence in these therapies. The exact mix of growth, margins, and dilution assumptions might surprise you.

According to this narrative, the model uses a discount rate of 7.15% to bring projected cash flows and earnings back to today’s dollars, and arrives at a fair value of $8.35 per share. That implies a large gap to the current $4.23 price, with the thesis built on high projected revenue growth, a move into positive profit margins, and a P/E on future earnings that sits far above the broader US Biotechs industry figure of 15.5x cited in the narrative’s assumptions.

Result: Fair Value of $8.35 (UNDERVALUED)

However, even this bullish setup runs into real friction, with heavy dependence on Amtagvi and lingering regulatory uncertainty around international approvals, both capable of upending the optimistic case.

Next Steps

With sentiment clearly split between risk and reward, it makes sense to move quickly, review the full picture yourself, and weigh both sides through 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop at a single stock, you risk missing out on other opportunities that might suit your goals even better, so broaden your search with a few focused screens.

• Spot potential turnaround stories early by scanning 24 elite penny stocks with strong financials that pair smaller share prices with stronger fundamentals than you might expect.
• Target quality at a price that could make more sense for you by reviewing 49 high quality undervalued stocks identified on cash flows and balance sheet strength.
• Prioritize resilience first by checking 61 resilient stocks with low risk scores that score well on financial health and lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.